---

Nanotheranostics: A powerful next-generation solution to tackle the chronic disease

Full Text PDF Share on Facebook Share on Twitter

---

Review Article

Author Details : M. Gandhi*, M. Boghara

Volume : 9, Issue : 1, Year : 2024

Article Page : 37-44

https://doi.org/10.18231/j.ijcaap.2024.006

Suggest article by email

Get Permission

Abstract

The use of nanotheranostics is the most advanced diagnostic and therapeutic techniques for a variety of disorders like cancer, IDs, HIV has drawn significant interest in the last ten years. Currently, various methods are use in the development of bright nanotheranostics, which mix bioactive concentrating on particular tissues and diagnostic capabilities. By using nanotheranostics, keeping track the therapy responses in real-time and therapeutic drugs is delivered. As a result, there is less chance of consuming too much medication. Several non-intrusive Imaging methods have been applied to track the medication distribution processes quantitatively. Radiolabeling of nanoparticles is a popular and effective method of nuclear diagnostics imaging in medicine. Numerous nanoparticles really have been created and they have effective qualities, they were created for imaging tumors and other lesions because of their effective qualities. Multifunctional nanotheranostics have been described for inorganic nanoparticles like gold, silver, silica-based nanomaterials, or organic nanoparticles including polymers, carbon-based nanomaterials, and liposomes. A summary of the most recent nanotheranostics organized according to the utilized nanomaterials is provided. Finally, as material scientists who work in the field of nanotheranostics can use this review as a guide to create newer and more effective nanotheranostics, it can be advantageous to the medical and pharmaceutical communities as well as of society.

Keywords: Nanotheranostics, Radiolabeling, Nanoparticles, Cancer, IDs, HIV

How to cite : Gandhi M, Boghara M, Nanotheranostics: A powerful next-generation solution to tackle the chronic disease. IP Int J Compr Adv Pharmacol 2024;9(1):37-44

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.